{
    "organizations": [],
    "uuid": "86c749ae15d39639c0ce139d6d03ae9480126fcd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-european-medicines-agency-accepts/brief-european-medicines-agency-accepts-biomarins-marketing-application-for-pegvaliase-idUSFWN1RA0YK",
    "ord_in_thread": 0,
    "title": "BRIEF-European Medicines Agency Accepts Biomarin's Marketing Application For Pegvaliase",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 28 (Reuters) - Biomarin Pharmaceutical Inc:\n* EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS BIOMARINâ€™S MARKETING APPLICATION FOR PEGVALIASE MAA FOR TREATMENT OF PHENYLKETONURIA (PKU)\n* BIOMARIN PHARMACEUTICAL INC - FDA PDUFA ACTION DATE FOR PEGVALIASE IS MAY 25, 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-29T04:20:00.000+03:00",
    "crawled": "2018-03-29T16:02:46.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "biomarin",
        "pharmaceutical",
        "inc",
        "european",
        "medicine",
        "agency",
        "ema",
        "accepts",
        "biomarin",
        "marketing",
        "application",
        "pegvaliase",
        "maa",
        "treatment",
        "phenylketonuria",
        "pku",
        "biomarin",
        "pharmaceutical",
        "inc",
        "fda",
        "pdufa",
        "action",
        "date",
        "pegvaliase",
        "may",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}